•  

Posts Tagged: MI embedded management

Miroculus acquires Kapplex to advance diagnostics for complex diseases

Canadian innovation will give patients affordable, non-invasive, accurate test for cancer or infectious diseases; R&D team to remain in Toronto discovery district TORONTO and SAN FRANCISCO (May 3, 2016) — Miroculus, a San Francisco-based biotechnology company specializing in microRNA-based diagnostics, today announced an agreement to acquire Toronto-based Kapplex Inc. The Canadian company’s proprietary Digital Microfluidic (DMF) platform is built upon the research of Dr. Aaron Wheeler, a world-leader in microfluidics research at the University of Toronto. This announcement was covered in GenomeWeb and PeHub. When ... Read more

MaRS Innovation featured in International Innovation magazine

MaRS Innovation and its member institutions are is profiled in International Innovation's July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI's president and CEO, written by Rosemary Peters. The article is posted on the publication's website and viewable through a digital interface (pages 80 and 81). Here's an excerpt from Dr. Hofstein's comments: "Canada's academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the ... Read more

Huffington Post : MaRS Innovation among driving forces in Canada’s start-up landscape

In "Big-Brain Hunting: The Key to Supercluster Success," the Huffington Post's Pat Lynch investigates how and what makes start-ups successful. Attracting top-talent is listed as a major reason, but so is the environment required to give start-ups the tools they need to flourish. Lynch highlights MaRS Innovation as a driving force in sustaining the innovation industry in Canada by attracting big ideas and global talent, using former MI project manager Lyssa Neel as an example. Neel helped launch the education sector start-up Crowdmark, and ... Read more

What does MaRS Innovation’s funding extension mean for Toronto’s academic entrepreneurs?

Every six weeks, MaRS Innovation's marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI's activities or one of our start-up companies. You can read the original post on the MaRS blog. Created in 2008, MaRS Innovation (MI) bridges the chasm between the early-stage technologies emerging from its 16 member institutions and successful startup companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, business development, mentorship and intellectual property protection strategy, MI acts as ... Read more

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

TORONTO, Feb. 19, 2013 — Xagenic Inc., a privately-held molecular diagnostics company, today announced that it will receive up to $990,000 in funding from the Government of Canada to support design and development of the first lab-free molecular diagnostic platform with a 20-minute time to result. The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), made the announcement in the keynote speech at the Conference Board of Canada's Business Innovation Summit 2013 ... Read more

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed? MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ... Read more

UTEST program: Giving U of T students a new way to become their own bosses

"There is a path somewhere between extended study and becoming an office worker," wrote The Varsity's Angela Brock, in "Be Your Own Boss: Student entrepreneurs combine creativity and business to forge new career paths" (February 3, 2012). "As it turns out, there are plenty of opportunities for those looking to flex their entrepreneurial muscles without straying too far from the bosom of U of T." Brock's article describes UTEST, the joint U of T-MaRS Innovation program that helps students, faculty and recent ... Read more

Bedside Clinical Systems featured in Philadelphia’s MedCity News

Bedside Clinical Systems (BCS) participated in Philadelphia's 2012 Canada-U.S. eHealth Summit on November 28. Twelve of the 65 participating companies were selected to pitch a group of over 100 chief medical information officers, chief information officers and chief medical officers from U.S. hospitals, along with venture capitalists and industry representatives. BCS's CEO Rajesh Sharma delivered a strong pitch and was interviewed for a story in MedCity News. (more…) Read more

VitalHub’s Chart Makes Apple’s Top 80 List of Doctor Apps

VitalHub Chart has been named to Apple's list of top 80 apps for doctors, nurses, patients and healthcare professionals in the "EMR and patient monitoring" category. Here's a description of the app, which is made by Toronto-based VitalHub Corp., from the Apple list curators: “VitalHub Chart puts patient data at your fingertips. You can access the information you need any time, anywhere there is WiFi or cellular service. No more waiting for a free desktop, hunting for a workstation on wheels, or carrying printouts ... Read more

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects. “Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to ... Read more
Page 1 of 212